Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2011-03-22
2011-03-22
Parkin, Jeffrey S. (Department: 1648)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C424S188100
Reexamination Certificate
active
07910716
ABSTRACT:
Embodiments of the invention provide processes for the selection of HIV-1 subtype (clade) C isolates, selected HIV-1 subtype C isolates, their genes and modifications and derivatives thereof for use in prophylactic and therapeutic vaccines to produce proteins and polypeptides for the purpose of eliciting protection against HIV infection or disease. A process for the selection of HIV subtype isolates comprises the steps of isolating viruses from recently infected subjects; generating a consensus sequence for at least part of at least one HIV gene by identifying the most common codon or amino acid among the isolated viruses; and selecting the isolated virus or viruses with a high sequence identity to the consensus sequence. HIV-1 subtype C isolates, designated Du422, Du 151 and Du 179 (assigned Accession Numbers 01032114, 00072724 and 00072725, respectively, by the European Collection of Cell Cultures) are also provided.
REFERENCES:
patent: 5817637 (1998-10-01), Weiner et al.
patent: 2005/0137387 (2005-06-01), Mullins et al.
patent: WO 02/04494 (2002-01-01), None
Brown, T., 1993, Hybridization analysis of DNA blots, in Current Protocols in Molecular Biology, John Wiley and Sons, Inc., 2.10.1-2.10.16.
Betts et al., “Cross-Clade Human Immunodeficiency Virus (HIV)-Specific Cytotoxic T-Lympocyte Responses in HIV-Infected Zambians,” J. Virol., 71:8908-8911, 1997.
Binley et al., “A Recombinant Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Complex Stabilized by an Intermolecular Disulfide Bond between the gp120 and gp41 Subunits Is an Antigenic Mimic of the Trimeric Virion-Associated Structure,” J. Virol., 74:627-643, 2000.
Connor et al., “Change in Coreceptor Use Correlates with Disease Progression in HIV-1-Infected Individuals,” J. Exp. Med., 185:621-628, 1997.
Durali et al., “Cross-Reactions between the Cytotoxic T-Lymphocyte Responses of Human Immunodeficiency Virus-Infected African and European Patients,” J. Virology, 1998, 72:3547-3553.
Ferrari et al., “Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers,” Proc. Natl. Acad. Sci. USA, 94:1396-1401, 1997.
Gao et al., “Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G,” J. Virology, 70:1651-1667, 1996.
Kostrikis et al., “Quantitative Analysis of Serum Neutralization of Human Immunodeficiency Virus Type 1 from Subtypes A, B, C, D, E, F, and I: Lack of Direct Correlation between Neutralization Serotypes and Genetic Subtypes and Evidence for Prevalent Serum-Dependent Infectivity Enhancement,” J. Virology, 70:445-458, 1996.
Koup et al., “Temporal Association of Cellular Immune Responses with the Initial Control of Viremia in Primary Human Immunodeficiency Virus Type 1 Syndrome,” J. Virology, 68:4650-4655, 1994.
Leigh Brown et al., “Reduced susceptibility of human immunodeficiency virus type 1 (HIV-1) from patients with primary HIV infection to nonnucleoside reverse transcriptase inhibitors is associated with variation at novel amino acid sites,” J. Virology, 74:10269-10273, 2000.
Lole et al., “Full-length Human Immunodeficiency Virus Type 1 Genomes from Subtype C-infected Seroconverters in India, with Evidence of Intersubtype Recombination,” J. Virology, 73:152-160, 1999.
Moore et al., “Inter- and Intraclade Neutralization of Human Immunodeficiency Virus Type 1: Genetic Clades Do Not Correspond to Neutralization Serotypes but Partially Correspond to gp120 Antigenic Serotypes,” J. Virology, 70:427-444, 1996.
Novitsky et al., “Molecular cloning and phylogenetic analysis of human immunofeficiency virus type 1 subtype C: a set of 23 full-length clones from Botswana,” J. Virology, 73:4427-4432, 1999.
Ogg et al., “Longitudinal Phenotypic Analysis of Human Immunodeficiency Virus Type 1-Specific Cytotoxic T Lymphocytes: Correlation with Disease Progression,” J. Virology, 73:9153-9160, 1999.
Rowland-Jones et al., “Cytotoxic T Cell Responses to Multiple Conserved HIV Epitopes in HIV-Resistant Prostitutes in Nairobi,” J. Clin. Invest., 102:1758-1765, 1998.
De Baar et al., “Subtype-specific sequence variation of the HIV type 1 long terminal repeat and primer-binding site,” Aids Res. and Human Retrovir., 16:499-504, 2000.
“HIV-1 Isolate BU/97/07, envelope,” EMBL Online, Jan. 2, 1996, Database accession No. H11U39249.
Tscherning et al., “Differences in chemokine coreceptor usage between genetic subtypes of HIV-1,” Virology, 241:181-188, 1998.
Van Harmelen et al., “A predominantly HIV Type 1 subtype C-restricted epidemic in South African urban populations,” Aids Res. and Human Retrovir., 15:395-398, 1999.
Bjorndal et al., “Phenotypic characteristics of human immunodeficiency virus type 1 subtype C isolates of Ethiopian AIDS Patients,” Aids Res. and Human Retrovir., 15:647-653, 1999.
Peeters et al., “Evidence for Differences in MT2 Cell Tropism According to Genetic Subtypes of HIV-1 : Syncytium-Inducing Variants Seem Rare Among Subtype C HIV-1 Viruses,” J. Acquir. Imm. Def. Synd., 20:115-121, 1999.
Ping et al., “Characterization of V3 Sequence Heterogeneity in Subtype C Human Immunodeficiency Virus Type 1 Isolates from Malawi: Underrepresentation of X4 Variants,” J. Virology, 73:6271-6281, 1999.
Richman et al., “The Impact of the Syncytium-Inducing Phenotype of Human Immunodeficiency Virus on Disease Progression,” J. Infect. Dis, 169:968-974, 1994.
Scarlatti et al., “In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression,” Nat. Med., 3:1259-1265, 1997.
Schmitz et al., “Control of Viremia in Simian Immunodeficiency Virus Infection by CD8+ Lymphocytes,” Science, 283:857-860, 1999.
Wyatt et al., “The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens,” Science, 280:1884-1888, 1998.
Summary Report: National HIV and Syphilis Sero-Prevalence Survey of Women Attending Public Antenatal Clinics in South Africa, Department of Health, Apr. 2001.
Office Action mailed Nov. 15, 2006 for U.S. Appl. No. 10/332,413.
Office Action mailed Jun. 22, 2006 for U.S. Appl. No. 10/332,413.
International Search Report mailed Dec. 2, 2002 for Application No. PCT/IB01/01208.
Summary Report: National HIV and Syphilis Sero-Prevalence Survey of women attending Public Antenatal Clinics in South Africa, Department of Health, 2000.
Korber et al., “Numbering Positions in HIV Relative to HXB2CG,” HIV Molecular Immunology Database, IV-27-35, 1998.
Robertson et al., “HIV-1 Nomenclature Proposal,” Science, 288:55-56, 2000.
Wyatt et al., “The Antigenic Structure of the HIV gp120 Envelope Glycoprotein,” Nature, 393:705-11, 1998.
Johnston Robert Edward
Karim Salim Abdol
Morris Lynn
Swanstrom Ronald
Williamson Carolyn
Alphavax, Incorporated
Kilpatrick Townsend & Stockton LLP
Medical Research Council
Parkin Jeffrey S.
University of Cape Town Observatory
LandOfFree
Nucleic acids encoding modified South African HIV-1 subtype... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nucleic acids encoding modified South African HIV-1 subtype..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleic acids encoding modified South African HIV-1 subtype... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2679801